Final Agenda 

 

Stem Cells 



 

 

Day 1 | Day 2 | Day 3 | Download Brochure 

Podcasts

 

 

Recommended Pre-Conference Short Course * 

(SC4) Identification, Characterization and Targeting of Cancer Stem Cells  

*Separate Registration Required. 

 

The new generation of stem cell research offers viable insights and resources of replacement cells to treat and reverse diseases, leading to regenerative medicine and ultimately personalized therapies. The primary objectives of Cambridge Healthtech Institute’s Stem Cells are the basics of regenerative medicine, including stem cell sources (embryonic, adult, cord blood or iPS) and technologies to harness their potential, pathways to deliver the new therapies, and translation of basic stem cell research into clinical applications.

 

 

Wednesday, February 23 

7:00 am Registration and Morning Coffee

8:00 Plenary Keynotes - Details 

9:40 Grand Opening Refreshment Break in the Exhibit Hall

 

STEM CELLS: ADVANCING REGENERATIVE MEDICINE 

11:00 Chairperson’s Opening Remarks

 

Keynote Presentation 

11:10 Novel Approaches to Stem Cell Based Lung, Kidney, Pancreatic and Intestinal Regenerative Therapies 

David WarburtonDavid Warburton, M.D., D.Sc., Professor, Director, Developmental Biology & Regenerative Medicine, Children’s Hospital Los Angeles, University of Southern California 

Amniotic fluid is a novel, ethically neutral and scalable source of stem cells, capable of contributing to tissues in all three germ layers. This talk will discuss possible applications of this approach to lung, kidney and pancreatic regenerative therapies. In addition, it will touch upon some promising approaches to stem cells based tissue engineering of hollow viscuses such as bronchus, intestine and the genitourinary tract. 

 

11:40 Engineering Stem Cell Microenvironments for Directed Differentiation

Todd McDevitt, Ph.D., Associate Professor, Biomedical Engineering, Georgia Institute of Technology

Stem cell phenotype is directly related to the summation of environmental cues capable of influencing cell fate decisions. Thus, integrating control of environmental factors via different types of engineering approaches enables new routes to direct differentiation of stem cells in more efficient, robust and scalable manners. We have examined the abilities of hydrodynamic forces and microsphere-mediated delivery to direct the differentiation and morphogenesis of pluripotent stem cell populations and found global and local effects on phenotypes, respectively. These environmental methods to modulate pluripotent differentiation are directly applicable to stem cell bioprocessing and biomanufacturing.

12:10 pm Differentiating Cardiac Cells for Regenerative Therapy

Kathryn Ivey, Ph.D., Staff Research Investigator, Stem Cell Core Director, Gladstone Institute of Cardiovascular Disease

Although ES and iPS cells hold great potential for regeneration and repair of injured tissues, such as diseased hearts, differentiating these pluripotent cells into the appropriate lineage(s) required for therapy can be challenging and inefficient.  We have been exploring the use of microRNAs to direct differentiation of mouse or human ES cells into the cardiac lineage.  More recently, we have identified factors that can directly program cardiac fibroblasts into functional cardiac muscle cells.  These types of approaches will impact the future of regenerative cardiac therapies.

    12:40 Luncheon Presentations(Sponsorship Opportunities Available) or Lunch on Your Own



1:45 Dessert in the Exhibit Hall

2:15 Chairperson’s Remarks

2:20 Effects of Long Term Culture on Human Embryonic Stem Cell Aging

Andrew Lee, Ph.D. Candidate, Medicine, Radiology, Stanford University

Pluripotent stem cells are a leading candidate for regenerative therapies because of their potential to form any cell type of the adult human body and their capacity for unlimited self renewal; however, a number of hurdles currently prevent the safe and efficacious translation of these therapies to the clinic. Challenges include prolonged in vitro culture of pluripotent stem cell lines, failure of therapeutic derivatives to engraft following in vivo transplantation, and potential for teratoma formation. This talk will summarize progress in addressing these issues for the future clinical application of pluripotent stem cell based therapies.

2:50 Combinatorial Development of Biomaterials for Tissue Engineering and Drug Delivery

Daniel G. Anderson, Ph.D., Professor, Chemical Engineering, Harvard-MIT Division of Health Sciences & Technology, David H. Koch Institute for Integrative Cancer Research

High throughput, combinatorial approaches have revolutionized small molecule drug discovery.  Here we describe our work on high throughput methods for developing and characterizing biomaterials for drug delivery and tissue engineering.  We have developed automated methods allowing for rapid nanoliter scale synthesis of 1000's of biomaterials, as well as the testing of their chemical, material, and biological properties.  These methods have also been applied towards the development of new methods to control stem cell behavior, as well as vehicles for drug delivery.  In particular, these combinatorial libraries of different biomaterials have enabled new methods for microparticulate drug delivery, non-viral gene therapy, siRNA delivery, and vaccines.

3:20 Using Testicular Germline Stem Cells for an in vitro Human Reproductive Toxicology Assay

Paul J. Turek, M.D., FACS, FRSM, President, American Society of Andrology; Director, The Turek Clinic

There is an unmet need for cost-effective bioassays that mimic human spermatogenesis for the preclinical evaluation of potentially toxic drugs and substances. In addition to more directly reflecting the human condition, cell based in vitro bioassays could streamline drug development by eliminating costly animal studies currently employed in drug testing paradigms. This lecture presents the biological rationale for, and feasibility of, a germline stem cell based model of human spermatogenesis.

3:50 Sponsored Presentations (Opportunities Available) 

4:20 Reception in the Exhibit Hall (Sponsorship Available) 

5:20 Breakout Discussions in the Exhibit Hall

Concurrent Problem Solving Break-Out Sessions are interactive, problem solving discussions hosted by a moderator to discuss a topic in depth.  The discussions are open to all attendees, sponsors, exhibitors, and speakers and provide a forum for discussing key issues and meeting potential partners. Please pick a topic of your choice and join in.  

 

Cardiac Induced Pluripotent Stem (iPS) Cells in Heart Repair and Regeneration
Moderator: Dinender K. Singla, Ph.D., Associate Professor of Medicine, Burnett School of Biomedical Sciences, College of Medicine, University of Central Florida 

  • Cardiac iPS cells may have advantage over Fibroblast iPS cells in heart regeneration
  • How to translate iPS cells into clinic compared with embryonic stem cells
  • Do we need tissue or patient specific iPS cells?
  • Safety issues in iPS cells

Monitoring Cellular Therapy by Noninvasive Imaging
Moderator: Joseph Frank, Ph.D., Senior Investigator, Frank Laboratory, Radiology and Imaging Sciences, NIH 

  • Approaches to labeling of cells 
  • Using imaging to monitor cell delivery - limitations and requirements 
  • How to translate technology to the clinic  

6:20 Close of Day



Day 1 | Day 2 | Day 3 | Download Brochure 

Japan-Flag Korea-Flag China-Simplified-Flag China-Traditional-Flag 

 

2015 MMTC Final Agenda 

Premier Sponsors:

Abbott Molecular 

Elsevier 


Jackson Laboratory - small logo 

Leica Biosystems 
 

 NanoString2   

 

Silicon Biosystems 

 

Singulex 

Thomson Reuters-Large 






Local Partners:

BayBio 


biocube 


Cabs 

City of SSF